Mateon Therapeutics, Inc.
701 Gateway Boulevard
South San Francisco
About Mateon Therapeutics, Inc.
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
48 articles with Mateon Therapeutics, Inc.
FDA Granted Pediatric Disease Designation for OXi-4503-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients
Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US Food and Drug Administration (FDA) granted our request and designate OXi4503 (combretastatin A1-diphosphate; CA1P) for treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease,” as defined in section 529(a)(3) of the Federal Food, Drug, and Cosmetic Act
Mateon’s Global Study for Artemisinin Intervention Against COVID-19 Cleared for Patient Enrollment in India
Mateon Therapeutics “Mateon”, a leading developer of TGF-β therapeutics for oncology and COVID-19, announced that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been cleared for patient enrollment in India.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Mateon Therapeutics announced the closing of the 1st tranche of financing related to the Mateon operations and spinoff of its EdgePoint AI, Inc..
Mateon and Asili Research Alliance Enter Into Partnership for the Development of Artemisinin Against Covid-19
Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced the launch of its global observational study called ARTI-19, for Artemisinin Intervention against COVID-19, in partnership with Asili Research Alliance of Tanzania.
Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.
Mateon is Selected by IBM Watson Health for the Use of IBM Clinical Development Solution at No Cost for Phase II Clinical Trial of OT-101 for COVID-19
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
Mateon Therapeutics, a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.
Mateon and GMP Completed Research and Service AgreementMateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19
Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announces that both Golden Mountain Partners (GMP) and Mateon have fulfilled all the obligations under the Research and Services Agreement (the “Agreement”) entered on February 3, 2020 and modified on March 22, 2020.
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of its first milestone and milestone payment by Autotelic BIO. OT-101 and IL-2 demonstrated good synergy against tumor xenograft model as an immune-oncology therapy. OT-101/IL-2 combination will advance to Phase 1 clinical development. AGOURA HILLS, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- Mateo
Mateon Announces an Expansion to its Pharmaceutical Manufacturing AI Camera Grid by Including Contact Tracing to Ensure Worker Safety
Mateon Therapeutics, Inc. – Mateon announced that EdgePoint AI, a division within Mateon, announced its decision to expand its manufacturing AI vision camera grid to encompass a contact tracing application which will monitor the spread of COVID-19 indoors.
Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun, Vuong Trieu. Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children. Clin Res Pediatr 2020; 3(1): 1-3 Fatih M. Uckun, Larn Hwang, Vuong Trieu. Selectively targeting TGF-β with Trabedersen/OT-101 in treatment of evolving and mild ARDS in
FDA Grants Pediatric Disease Designation for Mateon’s CA4PTreatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients
Mateon Therapeutics Inc. announced that the US Food and Drug Administration granted Rare Pediatric Disease Designation for CA4P/ Fosbretabulin for the treatment of of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease”.
5/4/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Mateon Therapeutics Inc. report several peer-reviewed publications derived from its R&D effort against COVID-19..
Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic. The proposed randomized, double-blind, placebo-controlled Phase 2 study is intended to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia in th
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements OT-101 which continues to demonstrate potent activity against SARS-CoV-2 and expands the company’s intellectual property portfolio AGOURA HILLS, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) today announced that its COVID-19 directed antiviral screening
Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19
Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to development OT-101, a TGF-β antisense drug candidate, announced today that Mateon has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT-101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500